Cannabis and AM251
Browse the latest research linking medical marijuana / medicinal cannabis and AM251 (a cannabinoid (synthetic))

Action: CB1 inverse agonist
AM-251 is an inverse agonist at the CB1 cannabinoid receptor. AM-251 is structurally very close to SR141716A (rimonabant); both are biarylpyrazole cannabinoid receptor antagonists [Wikipedia]
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
AM251 sleep in rats via experiment AM-251, A Cannabinoid Antagonist, Modifies the Dynamics of Sleep-Wake Cycles in Rats Jul 2019
AM-251 induced a dose- and time-dependent increase in the number of bouts in active wake (AW), and it decreased this number in all other vigilance states except in passive wake (PW). In contrast, the bout duration in PW compensatory decreased.
AM251 diabetes in mice Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice. Feb 2008
Ingestion Method: 6 mg/kg
These data indicate that sub-chronic antagonism of the cannabinoid CB1 receptor by daily treatment with AM251 counters aspects of the hyperphagia-related impairment of ob/ob mouse metabolism. Such effects seem predominantly mediated by restriction of energy intake.
AM251 opioid in rats via experiment (n=122) Cannabinoid CB1 receptors mediate the effects of corticotropin-releasing factor on the reinstatement of cocaine seeking and expression of cocaine-induced behavioural sensitization Apr 2012
Ingestion Method: intravenous
Action Pathway: CRF,CB1
The CB1 receptor antagonist, AM251, blocked CRF-induced reinstatement of cocaine seeking but was without effect on footshock- or cocaine-induced reinstatement of cocaine seeking